An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers When Fostamatinib Disodium 150 mg is Administered Alone and in Combination With Verapamil.

Trial Profile

An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers When Fostamatinib Disodium 150 mg is Administered Alone and in Combination With Verapamil.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Fostamatinib; Verapamil
  • Indications Angina pectoris; Arrhythmias; B cell lymphoma; Chronic lymphocytic leukaemia; Hypertension; Rheumatoid arthritis; Solid tumours; T cell lymphoma; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jan 2016 Results of this and other two phase I studies published in the Drugs in R and D
    • 22 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2010 Actual initiation date added to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top